Rapamycin is a prescription medication, originally used to prevent organ transplant rejection and in certain cancers, that has become one of the most discussed compounds in serious longevity science because of its effect on the mTOR pathway. Its use for longevity is off-label, experimental, and a subject of active clinical research.
Rapamycin has among the strongest evidence of any compound for extending lifespan in animal models, which is why it is taken seriously in longevity science. However, its longevity use in humans is not established, dosing for this purpose is not settled, and human trials (such as those examining intermittent low-dose regimens) are ongoing rather than concluded.
As an immunosuppressant, rapamycin affects immune function, which carries real risk including increased infection susceptibility, and it has other potential effects on blood sugar, lipids and wound healing. These are not trivial, and are why medical supervision is essential rather than optional.
Legal and prescription status: rapamycin is a prescription-only medicine, not a supplement, and its longevity use is off-label and experimental. It should only ever be considered under the supervision of a doctor familiar with this area, with appropriate monitoring. It must not be sourced or self-dosed outside a regulated prescription.
As a prescription medication, cost follows prescription pricing, and off-label longevity use is typically paid privately through specialist clinics.
Animal lifespan research on rapamycin and mTOR. Ongoing human trials on intermittent dosing. Educational information only. Prescription-only medicine, off-label longevity use is experimental.